Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910132 | 0.84 | KDM4E (0.47) | MEN1MAPTKMT2AKDM4ENSD2 | |
| SCHEMBL5940900 | 0.83 | AKR1C2 (0.64) | PLAUF2F10PLGPLAT | |
| SCHEMBL8431332 | 0.81 | MYC (0.43) | PLAUF2F10PLGPLAT | |
| SCHEMBL24800882 | 0.81 | MYC (0.43) | PLAUF2F10PLGPLAT | |
| SCHEMBL2070725 | 0.81 | AKR1C4 (0.67) | AKR1C4AKR1C3AKR1C2AKR1C1PTPN1 | |
| SCHEMBL13449170 | 0.79 | TTR (0.48) | PLAUF2F10PLGPLAT | |
| SCHEMBL21817721 | 0.79 | XDH (0.47) | PLAUF2F10PLGPLAT | |
| SCHEMBL24912687 | 0.79 | PLAU (0.43) | PLAUF2F10PLGPLAT | |
| SCHEMBL30063160 | 0.79 | XDH (0.47) | PLAUF2F10PLGPLAT | |
| SCHEMBL30307562 | 0.79 | PLAU (0.43) | PLAUF2F10PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4611741-A1 | TARGETING ALLOSTERIC AND ORTHOSTERIC POCKETS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4553075-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240383878-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118791498-A | Tetracyclic compound, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
| US-6683095-B2 | ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS | LG LIFE SCIENCES LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES LTD. (KR) | 2003-07-03 | — | — | US | disclosed |
| US-5574049-A | POTASSIUM CHANNEL OPENERS, BRONCHODILATORS, ANTIASTHMA | SANDOZ LTD. (CH) | 1996-11-12 | — | — | US | disclosed |
| EP-0623129-A1 | 2,2-DIALKYL- AND 2,2-DIALKYL-3,4-DIHYDRO-3-HYDROXY-2H-1-BENZOPYR ANS, THEIR USE AS PHARMACEUTICALS | Novartis AG (CH) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994012493-A1 | 2,2-DIALKYL- AND 2,2-DIALKYL-3,4-DIHYDRO-3-HYDROXY-2H-1-BENZOPYR ANS, THEIR USE AS PHARMACEUTICALS | SANDOZ, LTD. (CH) | 1994-06-09 | — | — | WO | disclosed |
| US-4002423-A | Benzofuran derivatives process for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | CDK4, CDK3, CDK6 | PLAU 2304/4885F2 2809/4885F10 2059/4885 |
| US-20240383878-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PLAU 4481/4885F2 3615/4885F10 2387/4885 |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | PIK3CA, PIK3R4, PIK3R1 | PLAU 4368/4885F2 4712/4885F10 3917/4885 |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | PLAU 4770/4885F2 4830/4885F10 4803/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PLAU 717/4885F2 685/4885F10 1442/4885 |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | PLAU 1917/4885F2 4727/4885F10 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.